Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer

Roberts, HN; Solomon, B; Harden, S; Lingaratnam, S; Alexander, M

Author(s): Roberts, HN; Solomon, B; Harden, S; Lingaratnam, S; Alexander, M;
Details: Publication Year 2024-07,Volume 25,Issue #5,Page e211-e220
Journal Title: Clinical Lung Cancer
Publication Type: Research article
Abstract: BACKGROUND: 30-day mortality after systemic anti-cancer therapy (SACT) has been suggested as a quality indicator primarily for measuring use of chemotherapy towards the end of life. Utility across different cancer types is unclear, especially when using immunotherapy and targeted therapies. METHODS: This retrospective study included patients with a diagnosis of lung cancer who received palliative-intent SACT at an Australian metropolitan cancer center between 2015 and 2022. Using a prospectively maintained lung cancer database, patient, disease, and treatment characteristics were evaluated against annual 30-day mortality rates following SACT. RESULTS: 1072 patients were identified. Annual 30-day mortality rate after palliative-intent SACT for lung cancer ranged between 9% and 15%, with significant variance between treatment types. Calculated rates of 30-day mortality are higher if longer reporting time periods are used. Patients who died within 30 days of SACT were more likely to have received targeted therapies or immunotherapy as their final line of treatment, have a poorer performance status at diagnosis, and have received multiple lines of treatment. CONCLUSIONS: Our data support differential interpretation of 30-day mortality for quality assurance, especially with regard to lung cancer. Consistency in population and reporting time periods, and accounting for treatment type is crucial if 30-day mortality is to be utilized as cancer care performance quality indicator. Relevance to quality care is questionable in the lung cancer setting.
Publisher: Elsevier
Keywords: Humans; *Lung Neoplasms/mortality/therapy/drug therapy/pathology; Male; Female; Retrospective Studies; Aged; Middle Aged; *Quality Indicators, Health Care; Australia/epidemiology; Aged, 80 and over; Palliative Care/methods; Immunotherapy/methods; Survival Rate; Benchmark; Chemotherapy; Immunotherapy; Quality assurance; Targeted therapy
Department(s): Medical Oncology; Pharmacy
Publisher's Version: https://doi.org/10.1016/j.cllc.2024.04.001
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-08-27 04:40:38

Last Modified: 2024-08-27 04:48:12